Bivalirudin

At a glance

Overview

Bivalirudin was designed from the thrombin-binding properties of hirudin, a natural anticoagulant originally identified in leeches. The resulting synthetic peptide acts directly without requiring antithrombin as a cofactor. Its short action and procedural evidence make it useful in selected coronary interventions, including situations where heparin is unsuitable. It is not a general-purpose chronic oral blood thinner and does not dissolve an established clot in the way a thrombolytic drug can. Clinical comparisons depend on the heparin regimen, platelet inhibitors, vascular access, and continuation strategy used, so historical trial advantages cannot be assumed to apply identically to every modern procedure.

Supporting sources [1] [2]

How it works

Bivalirudin binds thrombin at its catalytic site and an anion-binding region, inhibiting fibrin formation and thrombin-mediated platelet activation. It can act on circulating and clot-bound thrombin. Thrombin gradually cleaves the peptide, contributing to reversibility of the effect. Renal function influences clearance, so the duration and intensity of anticoagulation can change in kidney impairment even though the drug is commonly described as short acting.

Supporting sources [1] [2]

Where the approved evidence applies

Current US labeling covers anticoagulation during percutaneous coronary intervention, including patients with heparin-induced thrombocytopenia or associated thrombosis. The procedural setting permits close assessment of anticoagulant effect and bleeding. This indication does not establish bivalirudin as routine long-term prevention for every clotting disorder.

Supporting sources [1]

A comparison that depends on its comparator

In HORIZONS-AMI, bivalirudin reduced major bleeding and net adverse clinical events compared with heparin plus routine glycoprotein IIb/IIIa inhibition in patients undergoing primary PCI. The comparator included additional platelet inhibition, which matters when applying the finding. Acute stent-thrombosis risk also requires attention rather than focusing only on bleeding.

Supporting sources [1] [2]

Bleeding and acute stent thrombosis

Bleeding can occur at any site and may be life threatening. The label specifically warns about acute stent thrombosis in patients with ST-elevation myocardial infarction undergoing PCI. Kidney impairment changes exposure, and other anticoagulants or antiplatelet agents alter the overall bleeding–thrombosis balance.

Supporting sources [1]

Is it equivalent to a clot-dissolving medicine?

No. Inhibiting thrombin limits new fibrin formation and propagation of thrombosis. Thrombolytics act on a different process to break down fibrin. Bivalirudin’s role during coronary intervention is therefore determined by the procedure and accompanying medications, not by a general claim that peptide anticoagulants remove existing clots.

Supporting sources [1]